EUVIMEDEUVIMED entdecken
LeitlinieÜbersichtsarbeitOpen Access · CC BY 4.0

Diagnosis and treatment of invasive pulmonary aspergillosis in critically ill intensive care patients: executive summary of the German national guideline (AWMF 113-005)

Dominic Wichmann, Martin Hoenigl, Philipp Koehler, Christina Koenig, Frederike Lund, Sebastian Mang, Richard Strauß, Markus A Weigand, Christian Hohmann, Oliver Kurzai, Claus Heußel, Matthias Kochanek

Infection · 2025

DOI: 10.1007/s15010-025-02572-2 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Infection, 2025. Verfasst von Dominic Wichmann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. d.wichmann@uke.de. Hauptthemen laut MEDLINE: Invasive Pulmonary Aspergillosis, Antifungal Agents, Critical Care. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Hamburg-Eppendorf (UKE).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The executive summary of the guideline aims to provide the most relevant recommendations on the diagnosis and treatment of invasive pulmonary aspergillosis in critically ill patients in the intensive care unit.

Methods

The guideline’s work included a systematic literature search, selection and assessment of the data relevant to the issues identified. Key questions included the areas of epidemiology, risk factors, diagnostics, and therapy. They were discussed analogous to a PICO scheme within the guideline committee, with subsequent working groups proposing recommendations for specific key questions, which were then again discussed and finalized by the entire guideline committee.

Results

In addition to the classic risk factors (persistent neutropenia, allogeneic stem cell transplantation, congenital or acquired immunodeficiency, etc.), decompensated liver cirrhosis, COPD, solid tumours and viral pneumonia (influenza, COVID-19) have been established as risk factors for critically ill patients in need of intensive care. If there is no adequate improvement or even further clinical deterioration of the respiratory status in critically ill patients, the presence of IPA should be considered and appropriate diagnostic tests should be initiated. Diagnostics should include a CT scan of the chest and a broncho-alveolar lavage with culture for moulds, testing for galactomannan and PCR. Isavuconazole and voriconazole are recommended as first-line treatment, liposomal amphotericin B as an alternative, with posaconazole (PCZ) or the echinocandins (as an add-on to azole or polyene treatment) being additional options for salvage treatment.

Conclusion

Invasive aspergillosis in critically ill patients represents a diagnostic and therapeutic challenge. If indicated, invasive aspergillosis should be considered and appropriate diagnostic tests initiated. Isavuconazole and voriconazole are recommended as first-line treatment, liposomal amphotericin B as an alternative.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Invasive Pulmonary AspergillosisAntifungal AgentsCritical CareHumansCritical IllnessGermanyRisk FactorsIntensive Care UnitsCOVID-19Voriconazole

Stichwörter der Autor:innen

AzolesCritically ill patientsDrug interactionsGuidelineIntensive care medicineInvasive pulmonary aspergillosis

Substanzen

Antifungal AgentsVoriconazole

Autor:innen und Institutionen

  • Department of Intensive Care Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. d.wichmann@uke.de.
  • Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
  • Translational Mycology, ECMM Excellence Centre, Medical University of Graz, Graz, Austria.
  • Faculty of Medicine, Department I of Internal Medicine, University of Cologne, and University Hospital Cologne, Cologne, Germany.
  • Centre for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Division for Clinical Immunology, Cologne, Germany.
  • Department of Intensive Care Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

Förderung

  • Universitätsklinikum Hamburg-Eppendorf (UKE)

Zitieren

APA

Wichmann, D., Hoenigl, M., Koehler, P., Koenig, C., Lund, F., Mang, S., Strauß, R., Weigand, M. A., Hohmann, C., Kurzai, O., Heußel, C., & Kochanek, M. (2025). Diagnosis and treatment of invasive pulmonary aspergillosis in critically ill intensive care patients: executive summary of the German national guideline (AWMF 113-005). Infection. https://doi.org/10.1007/s15010-025-02572-2

Vancouver

Wichmann D, Hoenigl M, Koehler P, Koenig C, Lund F, Mang S, et al. Diagnosis and treatment of invasive pulmonary aspergillosis in critically ill intensive care patients: executive summary of the German national guideline (AWMF 113-005). Infection. 2025. doi:10.1007/s15010-025-02572-2

BibTeX
@article{Wichmann2025,
  author = {Wichmann, Dominic and Hoenigl, Martin and Koehler, Philipp and Koenig, Christina and Lund, Frederike and Mang, Sebastian and Strauß, Richard and Weigand, Markus A and Hohmann, Christian and Kurzai, Oliver and Heußel, Claus and Kochanek, Matthias},
  title = {Diagnosis and treatment of invasive pulmonary aspergillosis in critically ill intensive care patients: executive summary of the German national guideline (AWMF 113-005)},
  journal = {Infection},
  year = {2025},
  doi = {10.1007/s15010-025-02572-2}
}
Kostenlos starten →